J Orthop Surg Res:低剂量TP和ZA联合使用可用于骨折延迟愈合的治疗

2018-11-03 MedSci MedSci原创

骨折愈合延迟或不愈合可导致严重的后果,最近的研究报道,特立帕肽(TP)可有效促进愈伤组织形成,提高机械强度,且唑来膦酸盐(ZA)增加了大鼠骨折模型中骨折部位的愈伤组织大小和阻力。在这项研究中,研究人员评估了低剂量TP和ZA联合治疗对骨折愈合的影响。术后1周开始,将大鼠分成以下五组,TP(每周5次)和ZA(0.1mg/kg/次)给药方式:TP1μg组{T(1):TP1μg/kg},ZA组(ZA:0.

骨折愈合延迟或不愈合可导致严重的后果,最近的研究报道,特立帕肽(TP)可有效促进愈伤组织形成,提高机械强度,且唑来膦酸盐(ZA)增加了大鼠骨折模型中骨折部位的愈伤组织大小和阻力。在这项研究中,研究人员评估了低剂量TP和ZA联合治疗对骨折愈合的影响。

术后1周开始,将大鼠分成以下五组,TP(每周5次)和ZA(0.1mg/kg/次)给药方式:TP1μg组{T(1):TP1μg/kg},ZA组(ZA:0.1mg/kg),TP1μg+ ZA组{T(1)+ ZA:TP1μg/kg + ZA},TP10μg+ ZA组{T(10)+ ZA :TP10μg/kg + ZA},和对照组(C:盐水)。术后7周切除股骨,使用4点量表的软X射线图像评估骨融合。并且在脱矿质和非脱矿质标本中进行组织病理学检查。此外,所有标本都进行了射线照相联合量表。

结果显示,关于骨融合率,C,T(1),ZA,T(1)+ ZA和T(10)+ ZA组分别显示20.0%,55.6%,70.0%,70.0%和80.0%,并且在4分制中,每组分别为0.50,1.56,2.00,2.60和2.80分。T(1)+ ZA和T(10)+ ZA组中,愈伤组织体积分别明显增加至16.66mm 2和17.75mm 2,而在C组中则为10.65mm 2(p <0.05)。此外,T(10)+ ZA组的愈伤组织面积也明显增加至78.78%,而C和T(1)+ ZA组分别为54.63%和44.11%(p <0.01)。组织病理学上,在C组的骨连接处观察到软骨组织和未成熟的愈伤组织形成;然而,在ZA,T(1)+ ZA和T(10)+ ZA组中观察到成熟愈伤组织的骨桥形成。

综上所述,该研究结果表明,建议联合给予低剂量TP和ZA可用于骨折延迟愈合的治疗。我们希望联合治疗可能成为新的治疗策略之一。

原始出处:

Yuta Tsubouchi, Shinichi Ikeda, Combination therapy with low-dose teriparatide and zoledronate contributes to fracture healing on rat femoral fracture model. J Orthop Surg Res. 2018; 13: 267.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1480519, encodeId=8f771480519b9, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Nov 05 07:37:00 CST 2018, time=2018-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351533, encodeId=345d3515332c, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Nov 04 15:33:43 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351409, encodeId=647a3514092d, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Nov 03 20:40:46 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351399, encodeId=954f35139963, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 03 20:13:30 CST 2018, time=2018-11-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1480519, encodeId=8f771480519b9, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Nov 05 07:37:00 CST 2018, time=2018-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351533, encodeId=345d3515332c, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Nov 04 15:33:43 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351409, encodeId=647a3514092d, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Nov 03 20:40:46 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351399, encodeId=954f35139963, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 03 20:13:30 CST 2018, time=2018-11-03, status=1, ipAttribution=)]
    2018-11-04 清风拂面

    谢谢分享学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1480519, encodeId=8f771480519b9, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Nov 05 07:37:00 CST 2018, time=2018-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351533, encodeId=345d3515332c, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Nov 04 15:33:43 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351409, encodeId=647a3514092d, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Nov 03 20:40:46 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351399, encodeId=954f35139963, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 03 20:13:30 CST 2018, time=2018-11-03, status=1, ipAttribution=)]
    2018-11-03 天地飞扬

    了解一下,谢谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1480519, encodeId=8f771480519b9, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Nov 05 07:37:00 CST 2018, time=2018-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351533, encodeId=345d3515332c, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Nov 04 15:33:43 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351409, encodeId=647a3514092d, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Nov 03 20:40:46 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351399, encodeId=954f35139963, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Nov 03 20:13:30 CST 2018, time=2018-11-03, status=1, ipAttribution=)]
    2018-11-03 医者仁心5538

    学习了

    0